Biostatistics Shared Resource (BSSR)

Biostatistics Shared Resource services cover the spectrum of cancer-related research activities, including: experimental design, sample size calculation, randomization, analysis plans, data analysis, grant and manuscript preparation, full clinical trial support, and innovative targeted methods development.

Scheduling, Location, and Hours of Operation

Medical Educational Building, Biostatistics suite | Monday–Friday from 8 a.m.-5 p.m.
For non-cancer related research and/or trainees with quick consultation needs, please email the Biostatistics Consulting Service at
Submit a BSSR iLab request

Services and Technologies

The major categories of service provided by BSSR include grant development, collaboration, consultation, clinical trial support, and manuscript preparation.
Grant Development
  • Preliminary data analysis
  • Study design and development of statistical analysis plans
  • Hypothesis development
  • Attendance at Program and transdisciplinary team meetings
  • Developing databases for data capture and management
  • Mentoring junior investigators
  • Power and sample size calculations
  • Data analysis and interpretation of results
  • Preparing data summaries for abstracts and manuscripts
Clinical Trial Development, Monitoring, and Analysis
  • Comprehensive support for trials from development of the protocol and statistical analysis plan through implementation, monitoring, analysis and preparation of final reports and manuscripts.
  • BSSR faculty develop trial design (e.g., Bayesian adaptive designs and dose-finding trials) and advocate for trials that maximize efficiency while addressing the trial’s objectives, patient protection and confidentiality, and ethical considerations.
Manuscript Preparation
  • Data analysis
  • Preparation of tables and figures and text for Methods
  • Help with interpretation of results and reviewing the quantitative and statistical aspects of manuscripts



Paul Auer, PhD

Director, Biostatistics Shared Resource (BSSR)

Notable Publications

Comparison of multiple imputation and other methods for the analysis of imputed genotypes. (Auer PL, Wang G, Li G, DeWan AT, Leal SM) BMC Genomics 2023 Jun 06;24(1):303 PMID: 37277705 PMCID: PMC10242917 SCOPUS ID: 2-s2.0-85160972672 06/06/2023

Nonparametric failure time: Time-to-event machine learning with heteroskedastic Bayesian additive regression trees and low information omnibus Dirichlet process mixtures. (Sparapani RA, Logan BR, Maiers MJ, Laud PW, McCulloch RE) Biometrics 2023 Dec;79(4):3023-3037 PMID: 36932826 PMCID: PMC10505620 SCOPUS ID: 2-s2.0-85153305626 03/19/2023

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. (Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C) J Clin Oncol 2021 Oct 20;39(30):3328-3339 PMID: 34106753 PMCID: PMC8791814 SCOPUS ID: 2-s2.0-85112086284 6/10/2021

National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. (Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J) J Clin Oncol 2021 Jun 20;39(18):1971-1982 PMID 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 4/28/2021

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. (Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG) Blood 2021 Jan 21;137(3):420-428 PMID: 33475736 PMCID: PMC7819761 SCOPUS ID: 2-s2.0-85092507677 1/22/2021

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P) Nat Med 2020 Oct;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020

Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point. (Martens MJ, Logan BR) Lifetime Data Anal 2020 Jul;26(3):603-623 PMID: 31729633 PMCID: PMC7365590 SCOPUS ID: 2-s2.0-85075483839 11/16/2019

Racial disparities of liver cancer mortality in Wisconsin. (Bemanian A, Cassidy LD, Fraser R, Laud PW, Saeian K, Beyer KMM) Cancer Causes Control 2019 Dec;30(12):1277-1282 PMID: 31531799 PMCID: PMC6858574 SCOPUS ID: 2-s2.0-85073816952 9/19/2019